 Christie Beatson
Concepts (57)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoglycemic Agents | 7 | 2025 | 1387 | 0.900 |
Why?
| | Diabetes Mellitus, Type 1 | 11 | 2025 | 3890 | 0.710 |
Why?
| | Overweight | 4 | 2025 | 609 | 0.490 |
Why?
| | Glucagon-Like Peptides | 3 | 2025 | 70 | 0.430 |
Why?
| | Blood Glucose | 9 | 2025 | 2327 | 0.340 |
Why?
| | Obesity | 4 | 2025 | 3077 | 0.270 |
Why?
| | Blood Glucose Self-Monitoring | 4 | 2018 | 699 | 0.200 |
Why?
| | Drug Approval | 1 | 2024 | 89 | 0.200 |
Why?
| | Insulin | 4 | 2024 | 2507 | 0.190 |
Why?
| | Weight Loss | 2 | 2025 | 836 | 0.180 |
Why?
| | Diabetic Nephropathies | 1 | 2025 | 318 | 0.170 |
Why?
| | Postprandial Period | 2 | 2024 | 118 | 0.140 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2025 | 146 | 0.140 |
Why?
| | Insulin Infusion Systems | 2 | 2024 | 477 | 0.130 |
Why?
| | Eczema | 1 | 2018 | 66 | 0.130 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2024 | 2583 | 0.100 |
Why?
| | Skin | 1 | 2018 | 755 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2168 | 0.090 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2013 | 46 | 0.090 |
Why?
| | Pyrazines | 1 | 2013 | 92 | 0.090 |
Why?
| | Glucagon | 1 | 2013 | 112 | 0.090 |
Why?
| | Body Mass Index | 3 | 2025 | 2438 | 0.090 |
Why?
| | Triazoles | 1 | 2013 | 184 | 0.090 |
Why?
| | Infusions, Subcutaneous | 1 | 2011 | 24 | 0.080 |
Why?
| | Injections, Subcutaneous | 1 | 2011 | 164 | 0.080 |
Why?
| | Monitoring, Ambulatory | 1 | 2009 | 88 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2025 | 17066 | 0.060 |
Why?
| | Humans | 11 | 2025 | 144759 | 0.060 |
Why?
| | Adult | 8 | 2025 | 40449 | 0.060 |
Why?
| | Middle Aged | 6 | 2025 | 35875 | 0.050 |
Why?
| | Insulin, Short-Acting | 1 | 2024 | 8 | 0.050 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2024 | 13 | 0.050 |
Why?
| | Glucagon-Like Peptide-2 Receptor | 1 | 2024 | 16 | 0.050 |
Why?
| | Insulin, Regular, Human | 1 | 2024 | 47 | 0.050 |
Why?
| | Software | 1 | 2008 | 690 | 0.050 |
Why?
| | Administration, Inhalation | 1 | 2024 | 574 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2025 | 11679 | 0.050 |
Why?
| | Glomerular Filtration Rate | 1 | 2025 | 760 | 0.040 |
Why?
| | Male | 7 | 2025 | 72315 | 0.040 |
Why?
| | Female | 7 | 2025 | 78271 | 0.040 |
Why?
| | Glucose | 1 | 2024 | 1047 | 0.040 |
Why?
| | Blood Pressure | 1 | 2025 | 1769 | 0.030 |
Why?
| | Prospective Studies | 2 | 2024 | 7990 | 0.030 |
Why?
| | Hypoglycemia | 2 | 2009 | 477 | 0.030 |
Why?
| | Biomarkers | 1 | 2025 | 4271 | 0.020 |
Why?
| | Sitagliptin Phosphate | 1 | 2013 | 31 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 779 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2013 | 2029 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 530 | 0.020 |
Why?
| | Safety | 1 | 2009 | 356 | 0.020 |
Why?
| | United States | 1 | 2024 | 15966 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2027 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2009 | 1985 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3409 | 0.010 |
Why?
| | Algorithms | 1 | 2008 | 1837 | 0.010 |
Why?
| | Adolescent | 1 | 2013 | 22428 | 0.010 |
Why?
| | Aged | 1 | 2013 | 25913 | 0.010 |
Why?
|
|
Beatson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|